FDA grants EUA for GenBody's COVID-19 test

2021 11 04 23 31 0570 2021 11 04 Genbody 400

GenBody has received an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its nasal swab COVID-19 antibody test.

This is GenBody's second COVID-19 test to receive EUA from the FDA, the company said.

The company received a $10 million award from the U.S. National Institutes of Health under its Rapid Acceleration of Diagnostics initiative to increase COVID-19 testing capacity in the U.S.

GenBody's direct anterior nasal swab COVID-19 antigen test is the company's second test to receive FDA emergency use authorization. Image courtesy of GenBody.GenBody's direct anterior nasal swab COVID-19 antigen test is the company's second test to receive FDA emergency use authorization. Image courtesy of GenBody.
Page 1 of 137
Next Page